Post-earnings recap
Reported
Wed, Nov 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that while CRISPR Therapeutics did not provide specific revenue figures or guidance, the stock rose significantly by 10.81%. This increase may reflect investor confidence in the company's ongoing research and development efforts, particularly in gene-editing technologies. The positive stock reaction suggests that investors are optimistic about the company's future prospects despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.07 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed optimism about the future of their gene-editing initiatives. They noted the importance of their clinical trials and ongoing research efforts.
Management highlighted ongoing progress in gene-editing technologies.
They emphasized a strong pipeline of clinical trials.
The team remains focused on advancing their lead programs.